

XXX
**Congresso
Nazionale**

AIBT

Associazione Italiana
di Immunogenetica
e Biologia dei Trapianti

STRATEGIE DI DELISTING IN RICEVENTI DI TRAPIANTO DI RENE IPERIMMUNI CON O SENZA DESENSIBILIZZAZIONE CON IMLIFIDASE: ESPERIENZA IN EMILIA ROMAGNA



Napoli, 10-12 Ottobre 2024

Dr. Silvia Giuliodori

SSD Immunogenetica
dei Trapianti - AOU Parma

PAZIENTI IPERIMMUNIZZATI: QUALI OPZIONI ?

IPERIMMUNI: cPRA >90%

- Programmi di Paired kidney exchange
- Programmi di Acceptable mismatch
- Desensibilizzazione classica o IMLIFIDASE: riduzione livello anticorpi
- Programmi prioritari (PNI: anzianità dialitica 8 anni, cPRA>90%)
- Strategie di **DELISTING** delle specificità anticorpali

DELISTING DELLE SPECIFICITA' ANTICORPALI

- TARGET: Pazienti altamente sensibilizzati (cPRA> 98%)
- OBIETTIVO: cPRA <98% per aumentare la trapiantabilità (>2%)
- Calcolo del cPRA%: su una popolazione reale di donatori (ER-vPRA calculator)


CNT - PNI



EFFETTO «BOLO»


267 ISCRITTI AL PNI (31/12/23)
217 (81%) PRA 99-100%

ONT.es, PATHI



Mamode, Transpl Int 2022

French Guideline (Imlifidase)



Couzi, Transpl Int 2023




DELISTING Emilia-Romagna

STRATEGIA DI DELISTING A 2 STEP

- OBIETTIVO: PRA<98%

- STEP 1: PNI

- STEP 2: IMLIFIDASE




STEP 1: DELISTING PER PNI


Centro Nazionale Trapianti

PROTOCOLLO NAZIONALE IPERIMMUNI

OBIETTIVI:

- PRA < 98% (trapiantabilità > 2%)
- FC-XM NEG







MFI < 5000: > 50% FC-XM
NEGATIVO

	T-cell CDC +	T cell CDC –
C3d-binding +	58	12
C3d-binding –	3 ^a	104
	B-cell CDC +	B cell CDC –
C3d-binding +	44	6
C3d-binding –	4	39

C1q / C3d: PREDITTIVO
CDC-XM NEG

STEP 2: DELISTING PER IMLIFIDASE







DIL 1:16

Tambur, HLA 2022

(a)




(b) Survival proportions based on percent MFI reduction in 1:16 diluted serum



Timofoeva, Transpl Int 2021




Stratificazione del rischio immunologico



DELISTING Emilia-Romagna

STRATEGIA DI DELISTING A 2 STEP


OBIETTIVO: PRA<98%



I nostri pazienti

- PNI
- IMLIFIDASE

Patient	Pre-delisting I + II	Delisting step 1 I + II	Delisting step 2 I + II
1	99.48%	96.40%	93.13%
2	99.98%	99.79%	99.39%
3	99.98%	99.94%	98.76%



- OBIETTIVO: PRA < 98%
- STEP 1: PNI
- STEP 2: IMLIFIDASE

MONITORARE LE OFFERTE!

XXX
Congresso
Nazionale

AIBT
Associazione Italiana
di Immunogenetica
e Biologia dei Trapianti

Grazie per l'attenzione

Napoli, 10-12 Ottobre 2024